Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vir Biotechnology, Inc. - Common Stock
(NQ:
VIR
)
7.000
-0.325 (-4.44%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vir Biotechnology, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
February 23, 2023
Via
Benzinga
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday
February 23, 2023
Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose...
Via
Benzinga
Vir Biotechnology's Earnings Outlook
February 22, 2023
Via
Benzinga
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
February 22, 2023
Final draft guidance based on cost effectiveness evaluation of sotrovimab
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 23, 2023
February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Via
Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 21, 2023
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.
Via
Benzinga
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
February 21, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday
February 21, 2023
Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 21, 2023
Via
Benzinga
Overview Of Value Stocks In The Healthcare Sector
February 20, 2023
Via
Benzinga
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
February 16, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
5 Value Stocks In The Healthcare Sector
January 30, 2023
Via
Benzinga
Analyst Expectations for Vir Biotechnology's Future
January 27, 2023
Via
Benzinga
2 Fast-Growing Healthcare Stocks to Buy and Hold
December 02, 2022
The innovative companies have made great gains in a short period of time.
Via
The Motley Fool
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
February 16, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out
February 14, 2023
Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.
Via
Benzinga
Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
February 14, 2023
Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,...
Via
Benzinga
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
February 13, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Insiders Selling Meta Platforms And 3 Other Stocks
February 10, 2023
The Nasdaq dropped by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
February 02, 2023
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.
Via
InvestorPlace
7 Healthcare Stocks That Will Be Big Winners in 2023
January 31, 2023
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
January 27, 2023
Via
Benzinga
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
January 25, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
2 Stocks That Could Turn $100 Into $1,000 by 2028
January 22, 2023
These growth stocks have substantial tailwinds.
Via
The Motley Fool
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
December 21, 2022
– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 –
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
December 02, 2022
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding...
Via
Benzinga
European Official Says COVID-19 Booster Uptake Disappointing In The Region
November 25, 2022
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.